RxDoctor Payments Data

Dennis Fisher

San Francisco, CANPI 1740659747

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $319,943 of the $319,943 with a category attached, or 100.0%. 7 manufacturers reported payments, led by AMAG Pharmaceuticals, Inc. at 39.8% of the total. Reporting peaked in 2023 at $175,350 and has fallen 93.9% since, to $10,673 in 2025.

$319,943in general payments, 2019–2025

Across 48 payments — averaging $6665.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AMAG Pharmaceuticals, Inc.$127K
  • Merck$115K
  • Janssen Research & Development, LLC$38K
  • Heron Therapeutics, Inc.$21K
  • Vanda Pharmaceuticals Inc.$10K
  • Takeda Pharmaceuticals U.S.A., Inc.$5K
  • plus $4K from 1 others
$1,769,187in research payments, 2019–2025

Across 158 payments — averaging $11,197 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vanda Pharmaceuticals Inc.$1.6M
  • Aquestive Therapeutics, Inc.$139K
  • Takeda Pharmaceuticals U.S.A., Inc.$11K
  • Pfizer$1K

What the payments were for

  • Consulting fees$319,943100%

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →